• Arrhythmia and treatment strategies.
• Image of the heart.
• Cardiovascular diseases.
• Cardiovascular disease risk factors and comorbidities: DM, HT, hyperlipidemia.
• Cardiovascular epidemiology and prevention.
• Cardiovascular surgery and interventional cardiology.
• Coronary artery diseases.
• Heart failure and cardiomyopathies.
• Heart transplantation.
• Key messages and recommendations of the new guidelines.
• Management of cardiovascular disease in women.
• Peripheral Artery Disease
• Telemedicine, artificial intelligence.
• Valvular heart disease.

• Primary and secondary arterial hypertension.
• Acute and chronic coronary syndromes
•  Disturbance of heart rhythm
• Acute and Chronic Heart Failure
• Cardiomyopathies
•  Inflammatory diseases of the heart
• Cardiac Rehabilitation
• Prevention of cardiovascular diseases in clinical practice
• Cardiac biomarkers
• Diabetes and cardiovascular diseases.
• Cardiac manifestations and complications in endocrine diseases
• Congenital heart disease in adults
• Cardiovascular diseases
• Cardiovascular surgery and interventional cardiology.
• Heart transplantation.
• Pathophysiology and pharmacotherapy of cardiovascular diseases
• Image of the heart
• Health organization and public health.
• Artificial intelligence and telemedicine in cardiology
• Cardio-Oncology
• Valvular diseases of the heart
• Peripheral Artery Disease

• Abstracts or Clinical cases should be written in A 4 format, size 12, Times New Roman font, line spacing 1.0.

•The abstract should occupy 1 page.

•Before the title of the abstract, the author's name and surname, full-time job title, scientific degree of the author, personal e-mail address and telephone number should be indicated on the right side.

•The abstract should be prepared under the following headings

o Title

o Background

o Methods (Problem presentation)

o Results

o Results

o Tables and figures - Upload a table or figure showing the results of your study.

• For interventional studies (eg, therapeutic trials), the type of design (prospective or retrospective, controlled or uncontrolled, randomized or observational, open and single-blind and double-blind), doses, assessment methods and follow-up should be specified.

• Nonspecific names of drugs should be used.

• Abbreviations should be used sparingly. For abbreviations, use the entire term first, followed by the standard abbreviation in parentheses.

• No less than 5 keywords should be written in Azerbaijani, Turkish and English languages.

The abstract is accepted in electronic form from February 5 to March 18, 2024 in Azerbaijani, Turkish and English languages (e-mail: info@tscc.az).

Deadline for abstract submission: March 24, 2024.

The scientific committee will select appropriate presentations from among the submitted presentations in accordance with the program of the congress. At the same time, a poster presentation can be submitted, and these presentations are also selected by the committee.

Selection process: a selection committee will review the final highest-scoring abstracts to determine the finalists. Selected abstracts will be presented to the jury in a special session, including a question-and-answer session

Abstracts not selected for the YIA session will automatically be considered for another oral presentation or paper poster presentation.

Conditions:

- Your abstract(s) must be accepted at the Young Researchers Award Session at TSCC 2024

- You must lead your abstract(s).

- You must be under 45 years old

An author may submit only one topic per session. Submission date: February 5 - March 18, 2024

Researchers whose abstracts are selected for presentation will be awarded.